Systematic analysis of post-translational regulation of autophagy protease ATG4B
Lead Research Organisation:
University College London
Department Name: MRC Cell Biology Unit
Abstract
Autophagy can be regarded as a cellular self-cleaning process through which damaged and potentially toxic components are removed through degradation. This process is involved in the clearance of protein aggregates (as for example in neurodegenerative disorders), damaged organelles (induced by cellular stresses or extracellular toxins) or pathogens (such as bacteria or viruses). In addition, autophagy counteracts the deleterious effects associated with ageing as it helps clear the accumulation of toxic protein products and damaged material that accumulates over time. Accordingly, it is of high importance that this process is tightly controlled. Dysregulation of autophagy is commonly associated with severe diseases that can lead to cancer, Parkinson's disease or Alzheimer's disease, just to name a few.
Autophagy can be induced through multiple mechanisms, including starvation, hypoxia, DNA damage or pathogen infection resulting in the formation of a double-membrane structure, the autophagosome. The autophagosome can remove defective organelles or complexes from cells and in most cases rescues the cell from potential harmful effects of the initial stressor. To understand these complex physiological conditions, it is of high importance to identify the molecular components involved and understand their interactions and regulation.
The autophagy machinery has been well characterized both in human cells and in yeast. There is one main question remaining in the field: that is to characterize the molecular mechanisms by which these proteins interact. Further, there is a huge interest in drug discovery to utilize this knowledge to develop therapeutic strategies for diseases associated with autophagy. Here, we aim to identify the molecular regulation of one of the key enzymes involved in autophagy, ATG4B. In order to identify the regulation of this protein, we will make use of recent technical advances in genomics and proteomics and use a combination of high-throughput screening technologies and proteomic profiling. There will be a huge benefit in identifying specific molecular targets within the autophagy pathway as this will enable more focused drug discovery efforts.
This project will shed light onto the signaling cascades that control an early step in autophagy and will provide to a general understanding of autophagy that will lead to the identification of potential novel therapeutic targets.
Autophagy can be induced through multiple mechanisms, including starvation, hypoxia, DNA damage or pathogen infection resulting in the formation of a double-membrane structure, the autophagosome. The autophagosome can remove defective organelles or complexes from cells and in most cases rescues the cell from potential harmful effects of the initial stressor. To understand these complex physiological conditions, it is of high importance to identify the molecular components involved and understand their interactions and regulation.
The autophagy machinery has been well characterized both in human cells and in yeast. There is one main question remaining in the field: that is to characterize the molecular mechanisms by which these proteins interact. Further, there is a huge interest in drug discovery to utilize this knowledge to develop therapeutic strategies for diseases associated with autophagy. Here, we aim to identify the molecular regulation of one of the key enzymes involved in autophagy, ATG4B. In order to identify the regulation of this protein, we will make use of recent technical advances in genomics and proteomics and use a combination of high-throughput screening technologies and proteomic profiling. There will be a huge benefit in identifying specific molecular targets within the autophagy pathway as this will enable more focused drug discovery efforts.
This project will shed light onto the signaling cascades that control an early step in autophagy and will provide to a general understanding of autophagy that will lead to the identification of potential novel therapeutic targets.
Technical Summary
Autophagy is a stress response that results in the activation of a lysosomal degradation pathway. Autophagy is a cellular process essential for homeostasis and has been implicated in the progression of ageing as well as various diseases including neurodegenerative diseases and cancer. Understanding this process at the molecular level is of high importance not only in the context of development of potential therapeutic strategies for disease, but also to understand this fundamental cellular process at the molecular level.
The signaling pathways that initiate autophagy are poorly understood and have centered on the serine/threonine kinase mammalian target of rapamycin (mTOR) as an inhibitor of autophagosome formation. In addition, several signaling molecules have been implicated in mTOR-dependent and mTOR-independent regulation of autophagy, such as phosphatidyl-inositol-3-kinase classes I and III, AKT1, PTEN, beclin-1 and Bcl2.
Mass spectrometry data have clearly indicated that autophagy proteins are controlled by post-translational modifications. However, none of the regulators of these modifications have yet been identified. The proposed project focuses on the identification of the molecular regulation of one specific autophagy gene, the autophagy protease ATG4B, which is the key regulator of LC3 proteolytic processing. We have previously described a cell-based assay system to monitor ATG4B proteolytic activity and used this system to identify kinases that control ATG4B activity in the basal state. Here, we plan to study the specific regulation of ATG4B activity under conditions that induce autophagy, such as oxidative stress, starvation and DNA damage induction using siRNA-based high-throughput screening and mass spetrometry. This study will provide important insights into the regulation of ATG4B and help elucidate signaling cascades that modulate autophagosome formation.
The signaling pathways that initiate autophagy are poorly understood and have centered on the serine/threonine kinase mammalian target of rapamycin (mTOR) as an inhibitor of autophagosome formation. In addition, several signaling molecules have been implicated in mTOR-dependent and mTOR-independent regulation of autophagy, such as phosphatidyl-inositol-3-kinase classes I and III, AKT1, PTEN, beclin-1 and Bcl2.
Mass spectrometry data have clearly indicated that autophagy proteins are controlled by post-translational modifications. However, none of the regulators of these modifications have yet been identified. The proposed project focuses on the identification of the molecular regulation of one specific autophagy gene, the autophagy protease ATG4B, which is the key regulator of LC3 proteolytic processing. We have previously described a cell-based assay system to monitor ATG4B proteolytic activity and used this system to identify kinases that control ATG4B activity in the basal state. Here, we plan to study the specific regulation of ATG4B activity under conditions that induce autophagy, such as oxidative stress, starvation and DNA damage induction using siRNA-based high-throughput screening and mass spetrometry. This study will provide important insights into the regulation of ATG4B and help elucidate signaling cascades that modulate autophagosome formation.
Planned Impact
Autophagy is a fundamental process in cell biology that is tightly connected to multiple cellular pathways such as cellular homeostasis, the metabolic state, energy production, mitogenic signaling, apoptosis and protein trafficking. The immediate goal of this project is to increase human knowledge and understanding about the regulation of this process. The importance of autophagy for cell survival and growth, as well as its involvement in multiple diseases, underscores its relevance for general health and well-being. The main benefectors from this study will be the research community that spans from areas of cell biology and biomedicine to drug discovery.
In the long-term, we aim to establish a relevance of the investigated pathway for biomedical research. Specifically, regulation of autophagy is involved in the development of disease. As such, the identification of the underlying pathways will help to determine potential disease marker and drug targets. Further, this information will help to identify strategies for the development of disease therapeutics. Accordingly, there is a high chance that intellectual property rights will be developed as a consequence of this study. To this end, we maintain links with MRC Technology and Transfer to discuss the potential generation of patentable ideas on a regular basis.
In a previous project, we have identified small molecules that modulate autophagy with the aim to develop potential therapeutic lead compounds. The proposed study is a direct follow-up of that work in order to identify the molecular targets for some of these compounds. As many pharmaceutical companies are desperately searching for new therapeutic targets at this moment, there will be a huge benefit in identifying kinases that modulate autophagy. In combination with our previous successful small molecule screening, there is a high chance for translational benefits of this project. We have already initiated discussions with MRCT about potential commercialization of this part of the project.
Training of skilled researchers is another major goal. The lab offers a perfect environment for providing a very broad and technology-driven training that includes expertise in cell biology, biotechnology engineering and bioinformatics. Researchers in my lab have access to a unique set of robotic automation resources that is not often found in academic settings. The postdoctoral research fellow will gain access to these instruments and learn how to operate them and how to handle large datasets. These are skills that are very useful and are only accessible in laboratories similar to the Translational Research Resource Centre at MRC LMCB.
In addition, this study will foster collaboration within different research groups across the world. This can be mainly achieved by exchange of knowledge in the form of publication and presentation at conferences, and in addition could take the form of national and international collaborations. For instance, there is already a close collaboration with Dr. Joern Dengjel at FRIAS in Germany in place. Dr. Dengjel is one of the world leading experts in proteomic analysis of autophagy proteins. As part of this project, visits to the mass spectrometry facility in Freiburg will take place and funds to facilitate these visits are requested.
Breakthrough findings will be communicated to the UCL press office. In addition, we will make all of our data publicly available, as well as any research tools including novel assay systems or bioinformatic databases.
As a consequence of this work, the prestige of our institute will increase in the scientific community, which will attract further financial support from funding agencies. The underlying mechanisms have implications for the development of biotechnology tools, thus attracting interest from the commercial sectors as well.
In the long-term, we aim to establish a relevance of the investigated pathway for biomedical research. Specifically, regulation of autophagy is involved in the development of disease. As such, the identification of the underlying pathways will help to determine potential disease marker and drug targets. Further, this information will help to identify strategies for the development of disease therapeutics. Accordingly, there is a high chance that intellectual property rights will be developed as a consequence of this study. To this end, we maintain links with MRC Technology and Transfer to discuss the potential generation of patentable ideas on a regular basis.
In a previous project, we have identified small molecules that modulate autophagy with the aim to develop potential therapeutic lead compounds. The proposed study is a direct follow-up of that work in order to identify the molecular targets for some of these compounds. As many pharmaceutical companies are desperately searching for new therapeutic targets at this moment, there will be a huge benefit in identifying kinases that modulate autophagy. In combination with our previous successful small molecule screening, there is a high chance for translational benefits of this project. We have already initiated discussions with MRCT about potential commercialization of this part of the project.
Training of skilled researchers is another major goal. The lab offers a perfect environment for providing a very broad and technology-driven training that includes expertise in cell biology, biotechnology engineering and bioinformatics. Researchers in my lab have access to a unique set of robotic automation resources that is not often found in academic settings. The postdoctoral research fellow will gain access to these instruments and learn how to operate them and how to handle large datasets. These are skills that are very useful and are only accessible in laboratories similar to the Translational Research Resource Centre at MRC LMCB.
In addition, this study will foster collaboration within different research groups across the world. This can be mainly achieved by exchange of knowledge in the form of publication and presentation at conferences, and in addition could take the form of national and international collaborations. For instance, there is already a close collaboration with Dr. Joern Dengjel at FRIAS in Germany in place. Dr. Dengjel is one of the world leading experts in proteomic analysis of autophagy proteins. As part of this project, visits to the mass spectrometry facility in Freiburg will take place and funds to facilitate these visits are requested.
Breakthrough findings will be communicated to the UCL press office. In addition, we will make all of our data publicly available, as well as any research tools including novel assay systems or bioinformatic databases.
As a consequence of this work, the prestige of our institute will increase in the scientific community, which will attract further financial support from funding agencies. The underlying mechanisms have implications for the development of biotechnology tools, thus attracting interest from the commercial sectors as well.
Organisations
- University College London (Lead Research Organisation)
- Samsara Therapeutics (Collaboration)
- University College London (Collaboration)
- British Columbia Cancer Agency (BCCA) (Collaboration)
- MRC-Technology (Collaboration)
- Institute of Cancer Research UK (Collaboration)
- Johnson & Johnson (Collaboration)
- Eisai Ltd (Collaboration)
- Thermo Fisher Scientific (United Kingdom) (Collaboration)
- Horizon Genomics (Collaboration)
- Albert Ludwig University of Freiburg (Collaboration)
- University of Toronto (Collaboration)
People |
ORCID iD |
Robin Ketteler (Principal Investigator) |
Publications
Agrotis A
(2015)
A new age in functional genomics using CRISPR/Cas9 in arrayed library screening.
in Frontiers in genetics
Pengo N
(2017)
A reversible phospho-switch mediated by ULK1 regulates the activity of autophagy protease ATG4B.
in Nature communications
Yao Z
(2015)
Application guide for omics approaches to cell signaling.
in Nature chemical biology
Luft C
(2014)
Application of Gaussia luciferase in bicistronic and non-conventional secretion reporter constructs.
in BMC biochemistry
Prak K
(2016)
Benzobisthiazoles Represent a Novel Scaffold for Kinase Inhibitors of CLK Family Members.
in Biochemistry
Ketteler R
(2017)
Corrigendum: Image-based siRNA screen to identify kinases regulating Weibel-Palade body size control using electroporation.
in Scientific data
Luft C
(2015)
Electroporation Knows No Boundaries: The Use of Electrostimulation for siRNA Delivery in Cells and Tissues.
in Journal of biomolecular screening
Klionsky DJ
(2016)
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
in Autophagy
Agrotis A
(2019)
Human ATG4 autophagy proteases counteract attachment of ubiquitin-like LC3/GABARAP proteins to other cellular proteins.
in The Journal of biological chemistry
Description | This grant has helped us to understand the regulation of autophagy, the cellular stress response, in more detail. We have been able to identify genes involved in the control of this process and discovered a novel mechanism of regulation that was previously not anticipated. |
Exploitation Route | The novel mechanisms of autophagy regulation that we have uncovered will generate multiple novel lines of research. For instance, a new concept of localized control of autophagy by kinases emerges that will be important in other areas of cell biology as well. Furthermore, there is the potential that some of the discovered genes are novel drug targets for pharmaceutical approaches. Also, this work has initiated discussions with pharmaceutical industry partners (AstraZeneca, J&J, Apollo Therapeutics, Samsara Therapeutics) and the identification of small molecule compounds for treatments of various forms of cancer. |
Sectors | Chemicals Healthcare Pharmaceuticals and Medical Biotechnology |
Description | Our findings are of high interest to a cell biology audience and will have impact for several areas: 1. the data help generate novel lines of research; 2. the data help understand animal health; 3. we have identified chemical compounds as novel research tools; |
First Year Of Impact | 2013 |
Sector | Chemicals,Education,Healthcare,Pharmaceuticals and Medical Biotechnology |
Description | Membership of Advisory Panel UCL-Eisai Collaboration |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | Michael J Fox Foundation Parkin Consortium |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Scientific Advisor to AstraZeneca High-Content Biology |
Geographic Reach | Europe |
Policy Influence Type | Participation in a guidance/advisory committee |
Description | The Royal Society Newton Fellowship panel member |
Geographic Reach | Multiple continents/international |
Policy Influence Type | Membership of a guideline committee |
Description | Action Medical Research PhD Fellowship |
Amount | £230,000 (GBP) |
Organisation | Action Medical Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2016 |
End | 08/2018 |
Description | Action Medical Research PhD Fellowship |
Amount | £230,000 (GBP) |
Organisation | Action Medical Research |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2016 |
End | 08/2018 |
Description | Eisai-UCL Collaboration Project TIG E |
Amount | £231,000 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 11/2017 |
End | 04/2020 |
Description | Eisai-UCL Collaboration Project TIG E |
Amount | £231,000 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 11/2017 |
End | 04/2020 |
Description | Michael J Fox Foundation |
Amount | $78,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 01/2014 |
End | 12/2014 |
Description | Michael J Fox Foundation |
Amount | $78,000 (USD) |
Organisation | Michael J Fox Foundation |
Sector | Charity/Non Profit |
Country | United States |
Start | 01/2014 |
End | 12/2014 |
Description | Targeting autophagy dependence in pancreatic cancer |
Amount | £109,341 (GBP) |
Funding ID | 2018RIF_15 |
Organisation | Pancreatic Cancer UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2019 |
End | 09/2023 |
Description | Targeting autophagy dependence in pancreatic cancer |
Amount | £109,341 (GBP) |
Funding ID | 2018RIF_15 |
Organisation | Pancreatic Cancer UK |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 08/2019 |
End | 09/2023 |
Description | UCL Confidence in Concept Award |
Amount | £99,208 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2014 |
End | 05/2015 |
Description | UCL Confidence in Concept Award |
Amount | £99,208 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 05/2014 |
End | 05/2015 |
Description | UCL Eisai collaboration |
Amount | £5,000,000 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 11/2017 |
End | 04/2019 |
Description | UCL Eisai collaboration |
Amount | £5,000,000 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 11/2017 |
End | 04/2019 |
Description | UCL-Eisai Collaboration |
Amount | £12,500 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 09/2016 |
End | 03/2017 |
Description | UCL-Eisai Collaboration |
Amount | £12,500 (GBP) |
Organisation | Eisai Ltd |
Sector | Private |
Country | Japan |
Start | 09/2016 |
End | 03/2017 |
Description | WT Institutional Strategic Support Fund |
Amount | £65,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2015 |
End | 12/2017 |
Description | WT Institutional Strategic Support Fund |
Amount | £65,000 (GBP) |
Organisation | Wellcome Trust |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 11/2015 |
End | 12/2017 |
Title | ATG4 Knockout cell lines |
Description | HeLa cell lines with knockout of ATG4A, B and C, generated by CRISPR/Cas9 genome editing. |
Type Of Material | Cell line |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | New insights into ATG4 biology that has led to collaborations with pharmaceutical partners. |
Title | ATG4 Knockout cell lines |
Description | HeLa cell lines with knockout of ATG4A, B and C, generated by CRISPR/Cas9 genome editing. |
Type Of Material | Cell line |
Year Produced | 2019 |
Provided To Others? | Yes |
Impact | New insights into ATG4 biology that has led to collaborations with pharmaceutical partners. |
Title | ATG4ABC CRISPR knockout cell line |
Description | HeLa cells with knockout of three proteins (ATG4A, B and C) generated by CRISPR/Cas9 genome editing |
Type Of Material | Cell line |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | This cell line will be useful for further research into the function of ATG4 proteases and can be used in early stage drug discovery for target validation. |
Title | ATG4ABC CRISPR knockout cell line |
Description | HeLa cells with knockout of three proteins (ATG4A, B and C) generated by CRISPR/Cas9 genome editing |
Type Of Material | Cell line |
Year Produced | 2018 |
Provided To Others? | Yes |
Impact | This cell line will be useful for further research into the function of ATG4 proteases and can be used in early stage drug discovery for target validation. |
Title | Antibody for phosphorylated ATG4B. |
Description | We have raised a polyclonal antibody for phosphorylated autophagy protease ATG4B. |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | This is the only available antibody to detect phosphorylated ATG4B at Serine 316 and will be a useful research tool to study the function of this protein. We expect that researchers will request this once our publication is accepted. We will happily provide this antibody to anyone interested. |
Title | Antibody for phosphorylated ATG4B. |
Description | We have raised a polyclonal antibody for phosphorylated autophagy protease ATG4B. |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | This is the only available antibody to detect phosphorylated ATG4B at Serine 316 and will be a useful research tool to study the function of this protein. We expect that researchers will request this once our publication is accepted. We will happily provide this antibody to anyone interested. |
Title | Inhibitor and activator compounds of ATG4B protease. |
Description | We have identified inhibitors, as well as activators of the autophagy protease ATG4B. |
Type Of Material | Technology assay or reagent |
Year Produced | 2018 |
Provided To Others? | No |
Impact | These compounds have therapeutic potential and we are further developing them into lead compounds for the treatment of cancer. |
Title | Inhibitor and activator compounds of ATG4B protease. |
Description | We have identified inhibitors, as well as activators of the autophagy protease ATG4B. |
Type Of Material | Technology assay or reagent |
Year Produced | 2018 |
Provided To Others? | No |
Impact | These compounds have therapeutic potential and we are further developing them into lead compounds for the treatment of cancer. |
Title | Modified luciferase release assay |
Description | This new version of a luciferase-based assay to monitor autophagy protease ATG4 activity can be used in academic research and drug target identification. The new version includes assays to monitor other protein targets of ATG4, such as LC3A and mutants thereof. |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | We have given the plasmid encoding this reporter to several other research groups. We are actively sharing this reagents with multiple labs and hope that this will advance research in this field. |
Title | Modified luciferase release assay |
Description | This new version of a luciferase-based assay to monitor autophagy protease ATG4 activity can be used in academic research and drug target identification. The new version includes assays to monitor other protein targets of ATG4, such as LC3A and mutants thereof. |
Type Of Material | Technology assay or reagent |
Year Produced | 2017 |
Provided To Others? | Yes |
Impact | We have given the plasmid encoding this reporter to several other research groups. We are actively sharing this reagents with multiple labs and hope that this will advance research in this field. |
Description | ATG4B compounds BC Cancer Agency |
Organisation | British Columbia Cancer Agency (BCCA) |
Country | Canada |
Sector | Public |
PI Contribution | We are assaying compounds that inhibit autophagy in our cell-based assays. |
Collaborator Contribution | Provision of chemical compounds for testing. |
Impact | No outcomes yet. |
Start Year | 2014 |
Description | ATG4B compounds BC Cancer Agency |
Organisation | British Columbia Cancer Agency (BCCA) |
Country | Canada |
Sector | Public |
PI Contribution | We are assaying compounds that inhibit autophagy in our cell-based assays. |
Collaborator Contribution | Provision of chemical compounds for testing. |
Impact | No outcomes yet. |
Start Year | 2014 |
Description | ATG4B compounds BC Cancer Agency |
Organisation | British Columbia Cancer Agency (BCCA) |
Country | Canada |
Sector | Public |
PI Contribution | We are assaying compounds that inhibit autophagy in our cell-based assays. |
Collaborator Contribution | Provision of chemical compounds for testing. |
Impact | No outcomes yet. |
Start Year | 2014 |
Description | ATG4B compounds BC Cancer Agency |
Organisation | British Columbia Cancer Agency (BCCA) |
Country | Canada |
Sector | Public |
PI Contribution | We are assaying compounds that inhibit autophagy in our cell-based assays. |
Collaborator Contribution | Provision of chemical compounds for testing. |
Impact | No outcomes yet. |
Start Year | 2014 |
Description | Arrayed CRISPR Library Screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher. |
Collaborator Contribution | ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project. |
Impact | We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016. |
Start Year | 2015 |
Description | Arrayed CRISPR Library Screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher. |
Collaborator Contribution | ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project. |
Impact | We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016. |
Start Year | 2015 |
Description | Arrayed CRISPR Library Screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher. |
Collaborator Contribution | ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project. |
Impact | We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016. |
Start Year | 2015 |
Description | Arrayed CRISPR Library Screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher. |
Collaborator Contribution | ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project. |
Impact | We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016. |
Start Year | 2015 |
Description | Arrayed CRISPR library screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | "We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher." |
Collaborator Contribution | "ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project." |
Impact | "We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016." |
Start Year | 2015 |
Description | Arrayed CRISPR library screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | "We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher." |
Collaborator Contribution | "ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project." |
Impact | "We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016." |
Start Year | 2015 |
Description | Arrayed CRISPR library screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | "We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher." |
Collaborator Contribution | "ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project." |
Impact | "We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016." |
Start Year | 2015 |
Description | Arrayed CRISPR library screening |
Organisation | Thermo Fisher Scientific |
Country | United States |
Sector | Private |
PI Contribution | "We are developing protocols for arrayed CRISPR library screening in partnership with ThermoFisher." |
Collaborator Contribution | "ThermoFisher has provided us with early access to a lentivirus library that is not yet commercially available. Also, Thermofisher is providing consumables and reagents for this research project." |
Impact | "We are currently preparing experiments for publication. Also, a Postdoc in the lab has presented preliminary results at the Wellcome Trust-AstraZeneca CRISPR conference in January 2016. Further, I have been invited to present these data at the CRISPR conference in Oxford in April 2016 and the GE/Dharmacon Functional Genomics meeting in London in April 2016." |
Start Year | 2015 |
Description | Chemistry of ATG4B Inhibitors |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed cell-based and in vitro assays to monitor autophagy protease activity. We work with researchers at UCL for provision of chemical libraries and chemistry to enable drug discovery projects. |
Collaborator Contribution | Provision of chemical compounds and expertise in chemistry. |
Impact | This partnership is multi-disciplinary and involves chemistry, biology and bioinformatics. |
Start Year | 2014 |
Description | Chemistry of ATG4B Inhibitors |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed cell-based and in vitro assays to monitor autophagy protease activity. We work with researchers at UCL for provision of chemical libraries and chemistry to enable drug discovery projects. |
Collaborator Contribution | Provision of chemical compounds and expertise in chemistry. |
Impact | This partnership is multi-disciplinary and involves chemistry, biology and bioinformatics. |
Start Year | 2014 |
Description | Chemistry of ATG4B Inhibitors |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed cell-based and in vitro assays to monitor autophagy protease activity. We work with researchers at UCL for provision of chemical libraries and chemistry to enable drug discovery projects. |
Collaborator Contribution | Provision of chemical compounds and expertise in chemistry. |
Impact | This partnership is multi-disciplinary and involves chemistry, biology and bioinformatics. |
Start Year | 2014 |
Description | Chemistry of ATG4B Inhibitors |
Organisation | University College London |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We have developed cell-based and in vitro assays to monitor autophagy protease activity. We work with researchers at UCL for provision of chemical libraries and chemistry to enable drug discovery projects. |
Collaborator Contribution | Provision of chemical compounds and expertise in chemistry. |
Impact | This partnership is multi-disciplinary and involves chemistry, biology and bioinformatics. |
Start Year | 2014 |
Description | Eisai Pharmaceuticals |
Organisation | Eisai Ltd |
Country | Japan |
Sector | Private |
PI Contribution | In collaboration with researchers at Eisai and funded through the Michael J Fox Foundation, we are exploring the role of De-ubiquitinating enzymes in Parkin-mediated mitophagy. We are providing the underlying cell biology for this study. |
Collaborator Contribution | Provision of a cDNA library and expertise in the field of neuro-degeneration. This has led to funding from the Michael J Fox Foundation for a pilot project. Since 2017, the partner has provided substantial funding for an early stage drug discovery project in my lab. This project has been initiated in 2017 and is ongoing. |
Impact | This collaboration has led to two successful funding applications. One is with the Michael J Fox Foundation. The other is with the industry partner itself, which is funding an early stage drug discovery project and a Postdoctoral scientist in the lab. |
Start Year | 2013 |
Description | Eisai Pharmaceuticals |
Organisation | Eisai Ltd |
Country | Japan |
Sector | Private |
PI Contribution | In collaboration with researchers at Eisai and funded through the Michael J Fox Foundation, we are exploring the role of De-ubiquitinating enzymes in Parkin-mediated mitophagy. We are providing the underlying cell biology for this study. |
Collaborator Contribution | Provision of a cDNA library and expertise in the field of neuro-degeneration. This has led to funding from the Michael J Fox Foundation for a pilot project. Since 2017, the partner has provided substantial funding for an early stage drug discovery project in my lab. This project has been initiated in 2017 and is ongoing. |
Impact | This collaboration has led to two successful funding applications. One is with the Michael J Fox Foundation. The other is with the industry partner itself, which is funding an early stage drug discovery project and a Postdoctoral scientist in the lab. |
Start Year | 2013 |
Description | Eisai Pharmaceuticals |
Organisation | Eisai Ltd |
Country | Japan |
Sector | Private |
PI Contribution | In collaboration with researchers at Eisai and funded through the Michael J Fox Foundation, we are exploring the role of De-ubiquitinating enzymes in Parkin-mediated mitophagy. We are providing the underlying cell biology for this study. |
Collaborator Contribution | Provision of a cDNA library and expertise in the field of neuro-degeneration. This has led to funding from the Michael J Fox Foundation for a pilot project. Since 2017, the partner has provided substantial funding for an early stage drug discovery project in my lab. This project has been initiated in 2017 and is ongoing. |
Impact | This collaboration has led to two successful funding applications. One is with the Michael J Fox Foundation. The other is with the industry partner itself, which is funding an early stage drug discovery project and a Postdoctoral scientist in the lab. |
Start Year | 2013 |
Description | Eisai Pharmaceuticals |
Organisation | Eisai Ltd |
Country | Japan |
Sector | Private |
PI Contribution | In collaboration with researchers at Eisai and funded through the Michael J Fox Foundation, we are exploring the role of De-ubiquitinating enzymes in Parkin-mediated mitophagy. We are providing the underlying cell biology for this study. |
Collaborator Contribution | Provision of a cDNA library and expertise in the field of neuro-degeneration. This has led to funding from the Michael J Fox Foundation for a pilot project. Since 2017, the partner has provided substantial funding for an early stage drug discovery project in my lab. This project has been initiated in 2017 and is ongoing. |
Impact | This collaboration has led to two successful funding applications. One is with the Michael J Fox Foundation. The other is with the industry partner itself, which is funding an early stage drug discovery project and a Postdoctoral scientist in the lab. |
Start Year | 2013 |
Description | ICR Kirkin |
Organisation | Institute of Cancer Research UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a research collaboration, which is lead by my team at UCL. |
Collaborator Contribution | The collaborator has given us access to important research tools and reagents and will contribute by performing in vivo studies in the future. |
Impact | None so far |
Start Year | 2018 |
Description | ICR Kirkin |
Organisation | Institute of Cancer Research UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a research collaboration, which is lead by my team at UCL. |
Collaborator Contribution | The collaborator has given us access to important research tools and reagents and will contribute by performing in vivo studies in the future. |
Impact | None so far |
Start Year | 2018 |
Description | ICR Kirkin |
Organisation | Institute of Cancer Research UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a research collaboration, which is lead by my team at UCL. |
Collaborator Contribution | The collaborator has given us access to important research tools and reagents and will contribute by performing in vivo studies in the future. |
Impact | None so far |
Start Year | 2018 |
Description | ICR Kirkin |
Organisation | Institute of Cancer Research UK |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | This is a research collaboration, which is lead by my team at UCL. |
Collaborator Contribution | The collaborator has given us access to important research tools and reagents and will contribute by performing in vivo studies in the future. |
Impact | None so far |
Start Year | 2018 |
Description | Johnson & Johnson |
Organisation | Johnson & Johnson |
Country | United States |
Sector | Private |
PI Contribution | We are screening a small molecule library from J&J with the aim to identify tool compounds that modulate breast cancer cell growth and autophagy. |
Collaborator Contribution | We have received a small molecule library targeting cysteine proteases for screening. |
Impact | Exchange of know-how and materials. |
Start Year | 2017 |
Description | Johnson & Johnson |
Organisation | Johnson & Johnson |
Country | United States |
Sector | Private |
PI Contribution | We are screening a small molecule library from J&J with the aim to identify tool compounds that modulate breast cancer cell growth and autophagy. |
Collaborator Contribution | We have received a small molecule library targeting cysteine proteases for screening. |
Impact | Exchange of know-how and materials. |
Start Year | 2017 |
Description | Johnson & Johnson |
Organisation | Johnson & Johnson |
Country | United States |
Sector | Private |
PI Contribution | We are screening a small molecule library from J&J with the aim to identify tool compounds that modulate breast cancer cell growth and autophagy. |
Collaborator Contribution | We have received a small molecule library targeting cysteine proteases for screening. |
Impact | Exchange of know-how and materials. |
Start Year | 2017 |
Description | Johnson & Johnson |
Organisation | Johnson & Johnson |
Country | United States |
Sector | Private |
PI Contribution | We are screening a small molecule library from J&J with the aim to identify tool compounds that modulate breast cancer cell growth and autophagy. |
Collaborator Contribution | We have received a small molecule library targeting cysteine proteases for screening. |
Impact | Exchange of know-how and materials. |
Start Year | 2017 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening. |
Collaborator Contribution | Provision of knockout cell lines and knockout cell panels free of charge. |
Impact | We are preparing experiments for publication. |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | "We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening." |
Collaborator Contribution | "Provision of knockout cell lines and knockout cell panels free of charge." |
Impact | "We are preparing experiments for publication." |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening. |
Collaborator Contribution | Provision of knockout cell lines and knockout cell panels free of charge. |
Impact | We are preparing experiments for publication. |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | "We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening." |
Collaborator Contribution | "Provision of knockout cell lines and knockout cell panels free of charge." |
Impact | "We are preparing experiments for publication." |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | "We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening." |
Collaborator Contribution | "Provision of knockout cell lines and knockout cell panels free of charge." |
Impact | "We are preparing experiments for publication." |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening. |
Collaborator Contribution | Provision of knockout cell lines and knockout cell panels free of charge. |
Impact | We are preparing experiments for publication. |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | "We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening." |
Collaborator Contribution | "Provision of knockout cell lines and knockout cell panels free of charge." |
Impact | "We are preparing experiments for publication." |
Start Year | 2015 |
Description | Knockout Cell Panel Screening |
Organisation | Horizon Genomics |
Country | United Kingdom |
Sector | Private |
PI Contribution | We are developing protocols for the use of CRISPR-engineered knockout cell panels in arrayed screening. |
Collaborator Contribution | Provision of knockout cell lines and knockout cell panels free of charge. |
Impact | We are preparing experiments for publication. |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds" |
Collaborator Contribution | "Provision of small molecule library" |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds" |
Collaborator Contribution | "Provision of small molecule library" |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds |
Collaborator Contribution | Provision of small molecule library |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds |
Collaborator Contribution | Provision of small molecule library |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds |
Collaborator Contribution | Provision of small molecule library |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds |
Collaborator Contribution | Provision of small molecule library |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds" |
Collaborator Contribution | "Provision of small molecule library" |
Impact | None to date |
Start Year | 2015 |
Description | MRCT Index Compound Set |
Organisation | MRC-Technology |
Country | United Kingdom |
Sector | Private |
PI Contribution | High-throughput screening of small molecule compounds" |
Collaborator Contribution | "Provision of small molecule library" |
Impact | None to date |
Start Year | 2015 |
Description | MaMTH EGFR Interactions |
Organisation | University of Toronto |
Country | Canada |
Sector | Academic/University |
PI Contribution | We are studying novel interaction partners of the EGFR that were identified using a technology developed in Igor Stagljar's lab at University of Toronto. |
Collaborator Contribution | Access to MaMTH, a novel method to identify protein-protein interactions. |
Impact | A publication has been published: Petschnigg et al. J Mol Biol 2017. |
Start Year | 2014 |
Description | MaMTH EGFR Interactions |
Organisation | University of Toronto |
Country | Canada |
Sector | Academic/University |
PI Contribution | We are studying novel interaction partners of the EGFR that were identified using a technology developed in Igor Stagljar's lab at University of Toronto. |
Collaborator Contribution | Access to MaMTH, a novel method to identify protein-protein interactions. |
Impact | A publication has been published: Petschnigg et al. J Mol Biol 2017. |
Start Year | 2014 |
Description | MaMTH EGFR Interactions |
Organisation | University of Toronto |
Country | Canada |
Sector | Academic/University |
PI Contribution | We are studying novel interaction partners of the EGFR that were identified using a technology developed in Igor Stagljar's lab at University of Toronto. |
Collaborator Contribution | Access to MaMTH, a novel method to identify protein-protein interactions. |
Impact | A publication has been published: Petschnigg et al. J Mol Biol 2017. |
Start Year | 2014 |
Description | MaMTH EGFR Interactions |
Organisation | University of Toronto |
Country | Canada |
Sector | Academic/University |
PI Contribution | We are studying novel interaction partners of the EGFR that were identified using a technology developed in Igor Stagljar's lab at University of Toronto. |
Collaborator Contribution | Access to MaMTH, a novel method to identify protein-protein interactions. |
Impact | A publication has been published: Petschnigg et al. J Mol Biol 2017. |
Start Year | 2014 |
Description | Mass Spectrometry of Autophagy |
Organisation | Albert Ludwig University of Freiburg |
Country | Germany |
Sector | Academic/University |
PI Contribution | In collaboration with Dr. Joern Dengjel at the University of Freiburg, we are using Mass Spectrometry to study signal transduction in autophagy. |
Collaborator Contribution | Access to mass spectrometer. |
Impact | Preliminary work has resulted in data for a BBSRC-funded project grant. |
Start Year | 2010 |
Description | Mass Spectrometry of Autophagy |
Organisation | Albert Ludwig University of Freiburg |
Country | Germany |
Sector | Academic/University |
PI Contribution | In collaboration with Dr. Joern Dengjel at the University of Freiburg, we are using Mass Spectrometry to study signal transduction in autophagy. |
Collaborator Contribution | Access to mass spectrometer. |
Impact | Preliminary work has resulted in data for a BBSRC-funded project grant. |
Start Year | 2010 |
Description | Mass Spectrometry of Autophagy |
Organisation | Albert Ludwig University of Freiburg |
Country | Germany |
Sector | Academic/University |
PI Contribution | In collaboration with Dr. Joern Dengjel at the University of Freiburg, we are using Mass Spectrometry to study signal transduction in autophagy. |
Collaborator Contribution | Access to mass spectrometer. |
Impact | Preliminary work has resulted in data for a BBSRC-funded project grant. |
Start Year | 2010 |
Description | Mass Spectrometry of Autophagy |
Organisation | Albert Ludwig University of Freiburg |
Country | Germany |
Sector | Academic/University |
PI Contribution | In collaboration with Dr. Joern Dengjel at the University of Freiburg, we are using Mass Spectrometry to study signal transduction in autophagy. |
Collaborator Contribution | Access to mass spectrometer. |
Impact | Preliminary work has resulted in data for a BBSRC-funded project grant. |
Start Year | 2010 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Testing small molecule compounds generated by the School of Pharmacy in autophagy assays. |
Collaborator Contribution | Generation and provision of 60 compounds for drug discovery. |
Impact | Invention Declaration Form has been filed with UCL-B. Discussions about licensing of compounds with industry partners started. |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | "Testing small molecule compounds generated by the School of Pharmacy in autophagy assays." |
Collaborator Contribution | "Generation and provision of 26 compounds for drug discovery." |
Impact | "Invention Declaration Form has been filed with UCL-B." |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | "Testing small molecule compounds generated by the School of Pharmacy in autophagy assays." |
Collaborator Contribution | "Generation and provision of 26 compounds for drug discovery." |
Impact | "Invention Declaration Form has been filed with UCL-B." |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Testing small molecule compounds generated by the School of Pharmacy in autophagy assays. |
Collaborator Contribution | Generation and provision of 60 compounds for drug discovery. |
Impact | Invention Declaration Form has been filed with UCL-B. Discussions about licensing of compounds with industry partners started. |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Testing small molecule compounds generated by the School of Pharmacy in autophagy assays. |
Collaborator Contribution | Generation and provision of 60 compounds for drug discovery. |
Impact | Invention Declaration Form has been filed with UCL-B. Discussions about licensing of compounds with industry partners started. |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | "Testing small molecule compounds generated by the School of Pharmacy in autophagy assays." |
Collaborator Contribution | "Generation and provision of 26 compounds for drug discovery." |
Impact | "Invention Declaration Form has been filed with UCL-B." |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | Testing small molecule compounds generated by the School of Pharmacy in autophagy assays. |
Collaborator Contribution | Generation and provision of 60 compounds for drug discovery. |
Impact | Invention Declaration Form has been filed with UCL-B. Discussions about licensing of compounds with industry partners started. |
Start Year | 2015 |
Description | Medicinal Chemistry of Autophagy modulators |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | "Testing small molecule compounds generated by the School of Pharmacy in autophagy assays." |
Collaborator Contribution | "Generation and provision of 26 compounds for drug discovery." |
Impact | "Invention Declaration Form has been filed with UCL-B." |
Start Year | 2015 |
Description | PROTAC Design for ATG4B |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing assays to monitor autophagy in pancreatic tumour cell lines with the aim to use these models to test small molecule compounds as potential therapeutics for pancreatic cancer. |
Collaborator Contribution | The Drug Discovery Group at UCL School of Pharmacy are collaborating in the design and development of PROTAC-based chemicals for treatment of pancreatic cancer. The collaborators perform chemical synthesis of novel compounds for this project. |
Impact | There are no outputs yet. There is potential for drug development and a potential benefit for patients with pancreatic cancer. |
Start Year | 2020 |
Description | PROTAC Design for ATG4B |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing assays to monitor autophagy in pancreatic tumour cell lines with the aim to use these models to test small molecule compounds as potential therapeutics for pancreatic cancer. |
Collaborator Contribution | The Drug Discovery Group at UCL School of Pharmacy are collaborating in the design and development of PROTAC-based chemicals for treatment of pancreatic cancer. The collaborators perform chemical synthesis of novel compounds for this project. |
Impact | There are no outputs yet. There is potential for drug development and a potential benefit for patients with pancreatic cancer. |
Start Year | 2020 |
Description | PROTAC Design for ATG4B |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing assays to monitor autophagy in pancreatic tumour cell lines with the aim to use these models to test small molecule compounds as potential therapeutics for pancreatic cancer. |
Collaborator Contribution | The Drug Discovery Group at UCL School of Pharmacy are collaborating in the design and development of PROTAC-based chemicals for treatment of pancreatic cancer. The collaborators perform chemical synthesis of novel compounds for this project. |
Impact | There are no outputs yet. There is potential for drug development and a potential benefit for patients with pancreatic cancer. |
Start Year | 2020 |
Description | PROTAC Design for ATG4B |
Organisation | University College London |
Department | School of Pharmacy |
Country | United Kingdom |
Sector | Academic/University |
PI Contribution | We are developing assays to monitor autophagy in pancreatic tumour cell lines with the aim to use these models to test small molecule compounds as potential therapeutics for pancreatic cancer. |
Collaborator Contribution | The Drug Discovery Group at UCL School of Pharmacy are collaborating in the design and development of PROTAC-based chemicals for treatment of pancreatic cancer. The collaborators perform chemical synthesis of novel compounds for this project. |
Impact | There are no outputs yet. There is potential for drug development and a potential benefit for patients with pancreatic cancer. |
Start Year | 2020 |
Description | Samsara Therapeutics |
Organisation | Samsara Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | We are providing expertise in autophagy assays and aging. |
Collaborator Contribution | The partner will provide small molecule chemical libraries and financial contribution. |
Impact | None so far |
Start Year | 2018 |
Description | Samsara Therapeutics |
Organisation | Samsara Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | We are providing expertise in autophagy assays and aging. |
Collaborator Contribution | The partner will provide small molecule chemical libraries and financial contribution. |
Impact | None so far |
Start Year | 2018 |
Description | Samsara Therapeutics |
Organisation | Samsara Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | We are providing expertise in autophagy assays and aging. |
Collaborator Contribution | The partner will provide small molecule chemical libraries and financial contribution. |
Impact | None so far |
Start Year | 2018 |
Description | Samsara Therapeutics |
Organisation | Samsara Therapeutics |
Country | United States |
Sector | Private |
PI Contribution | We are providing expertise in autophagy assays and aging. |
Collaborator Contribution | The partner will provide small molecule chemical libraries and financial contribution. |
Impact | None so far |
Start Year | 2018 |
Description | Academic RNAi Screening meeting |
Form Of Engagement Activity | Scientific meeting (conference/symposium etc.) |
Part Of Official Scheme? | No |
Type Of Presentation | workshop facilitator |
Geographic Reach | International |
Primary Audience | Other academic audiences (collaborators, peers etc.) |
Results and Impact | 120 Researchers attended a conference co-organized by Mike Howell, Steve Brown, Emma Shanks and myself. There were talks and panel discussions on this one-day meeting. The majority of attendants felt that the conference attracted important scientists in the field and many expressed the notion that this will impact the way they plan to do their research. Industrial partners have expressed satisfaction with the level of engagement with researchers, which will give them leads for commercialisation of their products. |
Year(s) Of Engagement Activity | 2011,2013,2014 |
Description | Autophagy UK Network meeting 2017 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Postgraduate students |
Results and Impact | 150 researchers, students, representatives from companies and journals came together to discuss the latest advances in the field of autophagy research in Longon. I was one of two organisers for the entire event. |
Year(s) Of Engagement Activity | 2017 |
URL | http://autophagy.uk |
Description | Royal Reception |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Supporters |
Results and Impact | The charitable organization Action Medical Research invited our research team to present at a Royal Reception at Buckingham Palace. HRH Prince Philip was hosting the event and there were approx 50-60 potential charitable donors present who engaged with our research presentation. The donors were very impressed and as a consequence willing to donate funding towards research into childhood diseases. A lot of the people reported that they learned something new and everyone was engaging in discussions around health, scientific research and patient benefit. |
Year(s) Of Engagement Activity | 2017 |
Description | School Visit (UCL Syddanmark, Denmark) |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Schools |
Results and Impact | 14 Students attended a workshop presentation and a tour of the high-throughput screening facility, which led to very fruitful discussion afterwards. The students were looking to explore career track options at that time. Several students indicated that they would now consider a career in science rather than as medical assistant. |
Year(s) Of Engagement Activity | 2014 |
Description | School visit |
Form Of Engagement Activity | Participation in an open day or visit at my research institution |
Part Of Official Scheme? | No |
Geographic Reach | Local |
Primary Audience | Schools |
Results and Impact | School visit with a tour of the MRC funded screening facility and demonstration of experiments |
Year(s) Of Engagement Activity | 2012,2013,2014,2015,2016 |
Description | Scientific Advisory Board Expert Panel for the Dementia Discovery Fund |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | International |
Primary Audience | Industry/Business |
Results and Impact | The Scientific Advisory Board of the Dementia Discovery Fund in collaboration with Alzheimers Research UK, invited me as an expert panel member to discuss the role of Autophagy in Alzheimer's disease. The SAB (composed of leading experts in the pharmaceutical industry and charities) explored the possbility to invest in the development of autophagy modulating drugs for treatment of Alzheimer's disease. This discussion had an immediate impact on funding decisions and the policy of the Dementia Discovery Fund going forward in this area. |
Year(s) Of Engagement Activity | 2019 |